Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein.
Deisy Segura-VillalobosDaniela Roa-VelázquezDan I Zavala-VargasJessica G Filisola-VillaseñorJorge Ivan Castillo ArellanoEdgar Morales RíosRicardo Reyes-ChilpaClaudia González-EspinosaPublished in: Pharmacological reports : PR (2022)
S-RBD domain promotes lung TNF-α and IL-6 production in a TLR4-dependent fashion in C57BL6/J mice. Xanthone Jacareubin possesses potential anti-COVID-19 properties that, together with the previously tested anti-inflammatory activity, safety, and tolerance, make it a valuable drug to be further investigated for the treatment of cytokine production caused by SARS-CoV-2 infection.
Keyphrases
- inflammatory response
- sars cov
- respiratory syndrome coronavirus
- toll like receptor
- lipopolysaccharide induced
- lps induced
- coronavirus disease
- immune response
- high glucose
- rheumatoid arthritis
- drug induced
- diabetic rats
- emergency department
- endothelial cells
- high fat diet induced
- protein protein
- human health
- risk assessment
- small molecule
- combination therapy
- high resolution
- amino acid
- mass spectrometry
- binding protein
- climate change
- wild type
- adipose tissue